Medifast

Medifast generates nearly all its revenue through the Optavia brand, which sells monthly subscription kits of branded meal replacements, bars, and shakes. Clients are paired with an independent coach — one of roughly 50,000 — who receives commissions on product sales. The company also earns a small fraction from its legacy Medifast medical-provider channel, but Optavia's direct-to-consumer recurring model dominates.

Medifast is a publicly traded operating company, not an investment fund or family office. It manufactures and distributes weight-management products under the Optavia and Medifast brands. However, its capital-allocation function has become more activist: the company deploys excess free cash flow into share buybacks and has historically carried zero long-term debt, making its balance sheet a topic of interest for allocators tracking corporate financial efficiency.

Capital-allocation decisions — including share repurchases, manufacturing capacity investments, and any M&A — are governed by the board of directors led by Chairman and CEO Daniel Chard. The company does not operate a separate corporate-venture arm or external-allocator function. As of 2025, the board's compensation committee includes executives with experience at Nu Skin and PepsiCo, bringing direct-selling and CPG operational backgrounds to resource-allocation votes.

Medifast's revenue peaked at $1.9 billion in 2022 as remote wellness demand surged during COVID, then contracted to $1.1 billion in fiscal 2024 as consumers returned to in-person options. The number of active Optavia coaches also declined, from a peak of roughly 65,000 to approximately 50,000. The company has responded by cutting corporate headcount and launching new product lines rather than pursuing a return to pre-pandemic revenue levels through acquisition.

Medifast does not run a venture-capital arm, corporate-venture unit, or private-equity fund. Its deployment is limited to internal capital expenditures — primarily manufacturing-capacity expansion at its Owings Mills, Maryland facility — and shareholder-return mechanisms including share buybacks. The company has not disclosed any minority-stake investments in external startups or health-tech platforms.

Medifast owns and operates a 400,000-square-foot manufacturing and distribution facility in Owings Mills, Maryland, where it produces its branded bars, shakes, and meal products. This vertical-integration approach differs from competitors who outsource production to contract manufacturers. The facility underwent a multi-year expansion completed in 2021, raising Medifast's self-manufacturing capacity to cover the majority of its product portfolio.

The Medifast Foundation is a separate 501(c)(3) philanthropic entity funded by Medifast Inc. and individual donors. Its primary focus is childhood-obesity prevention, executed through grants to community-based organizations and partnerships with entities like the YMCA. The foundation operates independently of the commercial coaching network, though Optavia coaches occasionally volunteer for foundation-run programs.